Publications by authors named "P de la Grange"
Background: In kidney transplantation, molecular diagnostics may be a valuable approach to improve the precision of the diagnosis. Using next-generation sequencing (NGS), we aimed to identify clinically relevant archetypes.
Methods: We conducted an Illumina bulk RNA sequencing on 770 kidney biopsies (540 kidney recipients) collected between 2006 and 2021 from 11 European centers.
Article Synopsis
- Syphilis cases among blood donors in France have been rising, with a significant uptick observed in 2022 compared to earlier years.
- Data from over 45 million donations (2007-2022) revealed that the infection rate was notably higher in males, particularly among men who have sex with men (MSM), whose risk factor percentage increased over time.
- A non-treponemic test (NTT) was used to assess infection recency, but the data were insufficient to reliably differentiate between recent and past infections among the syphilis-positive donors.
Article Synopsis
- Microsatellite instability (MSI), often linked to mismatch repair deficiency in colorectal cancer (CRC), leads to numerous noncoding DNA mutations, particularly affecting RNA splicing sites.
- This research shows that these noncoding mutations happen early in tumor development, even before the cancer cells become mutated in their coding regions, and are associated with altered splicing patterns in mRNA.
- The altered RNA splicing impacts cellular differentiation and promotes the initiation of MSI CRC, indicating that these noncoding changes are significant for cancer progression before traditional coding mutations occur.
Article Synopsis
- There is increasing interest in analyzing kidney biopsies through transcriptomic assessments to understand gene expression changes related to rejection.
- This study used next-generation sequencing (NGS) on RNA from 770 kidney biopsies to identify differentially expressed genes (DEGs) associated with antibody-mediated rejection (AMR) and T cell-mediated rejection (TCMR), revealing 603 and 1,186 new specific genes, respectively.
- Pathway analysis linked established panels to immunological processes in AMR and TCMR, while NGS uncovered novel transcripts that could inform future drug design and therapeutic strategies.
Article Synopsis
- Erythropoiesis-stimulating agents like erythropoietin (EPO) may negatively affect cancer patients due to their immunosuppressive properties.
- * In a mouse model of triple-negative breast cancer, EPO was found to promote tumor growth, create an 'immune desert,' and contribute to a 'cold tumor,' altering the immune cell distribution in various body areas.
- * EPO treatment specifically accelerates the activation and exhaustion of CD4 T cells, leading to an immunosuppressive tumor microenvironment, with a notable CD39 regulatory T cell population identified as a potential biomarker for increased tumor progression risk.